Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.(2019).
Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.Am J Hematol.(2019).
Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.Biol Blood Marrow Transplant.(2019).
A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.(2019).
Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia.Biol Blood Marrow Transplant.(2018).
Epigenetic modification enhances the cytotoxicity of busulfan and 4-hydroperoxycyclophosphamide in AML cells.Exp Hematol.(2018).
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant.(2018).
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis.Biol Blood Marrow Transplant.(2016).
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Cancer.(2016).
Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.Am J Hematol.(2016).
Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia.Biol Blood Marrow Transplant.(2016).